Mesoblast Limited vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Mesoblast Limited trades at $16.28 (market cap $2.17B), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $52.62. The key difference: First Trust NASDAQ Clean Edge Green Energy Idx Fd is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | QCLN | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $20.96 | $68.47 |
52-Week Low | $12.88 | $34.31 |
Enterprise Value | $2.17B | — |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
QCLN, a clean energy ETF, trades at $51.25, down 1.9% over 24 hours amid a bearish technical signal. The ETF faces headwinds from stalled U.S. renewable permits and supply chain pressures, though long-term demand for clean energy remains strong due to data center growth and global energy security concerns. Technical indicators show oversold conditions with RSI at 29.51, while moving averages signal a downtrend.
The outlook is cautious near-term due to policy uncertainty and cost inflation, but structural growth in low-emission power supports potential recovery. Risks include regulatory delays and Chinese trade tensions, while analyst sentiment is mixed with clean energy ETFs gaining attention for long-term energy transition themes.
Trailing returns across standard periods
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →